Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin
Conditions
Interventions
Moxetumomab Pasudotox
Locations
21
United States
Research Site
Phoenix, Arizona, United States
Research Site
Los Angeles, California, United States
Research Site
Chicago, Illinois, United States
Research Site
Bethesda, Maryland, United States
Research Site
Kansas City, Missouri, United States
Research Site
New York, New York, United States
Start Date
August 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
April 6, 2017
Lead Sponsor
MedImmune LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions